Skip to content

Just another WordPress site

Monthly Archives: February 2017

Redirecting N-Acetylaspartate Metabolism in the Central Nervous System Normalizes Myelination and Rescues Canavan Disease

Posted byJulianne TwiningFebruary 9, 2017February 6, 2020Posted inpress releaseLeave a comment on Redirecting N-Acetylaspartate Metabolism in the Central Nervous System Normalizes Myelination and Rescues Canavan Disease

Search for:

Recent Posts

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Announces Clinical Collaboration with Bristol Myers Squibb to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with OPDIVO® (nivolumab) in Advanced Solid Tumors with KRAS Mutations
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma Announces Collaborations with Three Academic Research Institutions
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Recent Comments

Archives

Categories

academic-partner
industry-partner
investor
media
news
partner
press release
Uncategorized

Meta

Log in
Entries feed
Comments feed
WordPress.org

bridgebiowp, Proudly powered by WordPress.